FDA Approves First Muscle-Targeted Treatment for Spinal Muscular Atrophy
Cambridge, Saturday, 12 September 2026.
Scholar Rock gained FDA approval for Isembyld, the first therapy directly targeting muscle loss in spinal muscular atrophy, driving a 15% stock surge ahead of its U.S. launch.
Regulatory Milestone and Market Reaction
Scholar Rock Holding Corporation (NASDAQ: SRRK) achieved a significant regulatory breakthrough on 2026-09-11, when the U.S. Food and Drug Administration approved ISEMBYLD™ (apitegromab-mstn) for treating spinal muscular atrophy (SMA) [2][5]. This approval covers adults and children aged two years and older who are currently receiving survival motor neuron 2 (SMN2)-targeted treatment [2][5]. Following the announcement, market reaction was immediate, with stock value rising 15% in after-hours trading as investors priced in the commercial potential of the new therapy [4]. The company confirmed that the U.S. commercial launch initiated on 2026-09-11, with product shipping expected to commence in the coming days [2][5].
Clinical Efficacy and Study Data
The approval was grounded in data from the Phase 3 SAPPHIRE clinical trial, which evaluated 188 patients aged 2 to 21 years across nine countries [2][5]. In the study, patients receiving the recommended 10 mg/kg dosage of ISEMBYLD demonstrated a 2.2-point improvement in motor function on the Hammersmith Functional Motor Scale-Expanded (HFMSE) compared to placebo after one year [2][5]. Furthermore, 34.2% of patients treated with ISEMBYLD achieved a ≥3-point HFMSE increase, compared to 13.5% on placebo, representing a 20.7 percentage point difference in meaningful motor function gains [2][5]. This data supports the classification of ISEMBYLD as the first muscle-targeted treatment for SMA, distinct from existing therapies that target motor neurons [1][2].
Safety Profile and Risk Factors
While the efficacy data is robust, the safety profile includes specific risks that investors and clinicians must monitor. Clinical data indicates a potential risk of bone fractures, including serious fractures, which may occur with or without injury during treatment [2][5]. Common side effects reported in the safety database of over 500 individuals include upper respiratory tract infections, vomiting, cough, viral infections, headache, gastroenteritis, pharyngitis, and hypersensitivity [2][5]. Scholar Rock disclosed these risk factors in regulatory filings, noting that such safety outcomes could lead to potential treatment discontinuation [2][5].
Commercial Strategy and Future Filings
Scholar Rock is actively engaging physicians, SMA care teams, and payers to support the product launch through its Scholar Rock Supports™ assistance program [2][5]. Looking beyond the U.S., the company intends to pursue regulatory approval and commercial launch of apitegromab in geographies outside the U.S., including a targeted regulatory filing in Japan by 2026-12-31 [4][5]. Previously, the company withdrew its European regulatory application in August 2026 to address manufacturing plant issues but plans to refile using an alternative facility [4]. To discuss the approval and commercial strategy further, management scheduled an investor conference call for 2026-09-14 at 8:00 a.m. ET [2][5].
Investment Implications and Outlook
The approval marks a pivotal phase for Scholar Rock, potentially impacting its commercial prospects and valuation in the biotechnology sector [1]. Upon approval, the company received a Rare Pediatric Disease Priority Review Voucher, which can be utilized for future marketing application priority reviews [5]. Retail sentiment for SRRK stock shifted to ‘bullish’ following the news, with the stock value up 26% year-to-date as of 2026-09-10 [4]. The company maintains a policy of not updating forward-looking statements unless mandated by law, emphasizing the importance of the upcoming investor call for further guidance [5].